Hypothesis

Berberine lowers the rate of epigenetic informational entropy by simultaneously increasing autophagic clearance of damaged histones and reducing UHRF1‑mediated maintenance of faulty DNA methylation, thereby decelerating DNA methylation‑based aging clocks such as DunedinPACE.

Mechanistic Rationale

• Berberine activates lysosomal AMPK via an AXIN1‑dependent pathway that is distinct from metformin, leading to robust stimulation of the ULK1/Beclin‑1/LC3 autophagy cascade [2][3]. This heightened autophagic flux promotes turnover of oxidized and mis‑placed histones, preventing the accumulation of chromatin defects that contribute to epigenetic noise.
• Parallelly, berberine downregulates UHRF1 expression and its interaction with AMPKα1, weakening the enzyme’s role in copying methylation patterns during DNA replication [2]. Lower UHRF1 activity reduces the propagation of methylation errors, limiting stochastic drift at CpG sites, especially in subtelomeric regions where entropy reflects telomere‑proximal informational loss.
• By decreasing HNF1α via the ubiquitin‑proteasome pathway, berberine also inhibits PCSK9, indirectly modulating liver‑derived bile acid pools that can influence FXR‑dependent chromatin remodeling in peripheral tissues [4]. Altered bile acid signaling may further stabilize nucleosome positioning, adding another layer of entropy control.
• Collectively, these actions target the two principal sources of epigenetic informational entropy: (1) defective histone carriers and (b) inaccurate methylation copying. Reducing either source should lower the overall entropy measured by epigenetic clocks.

Predictions & Experimental Design

1. In vivo treatment: Aged C57BL/6 mice receive berberine (200 mg/kg/day) or vehicle for 6 months.
2. Readouts:
   • Measure DunedinPACE acceleration from whole‑blood DNA.
   • Quantify subtelomeric methylation variance using targeted bisulfite sequencing.
   • Assess hepatic and muscle autophagy flux via LC3‑II/I ratios and p62 degradation.
   • Determine UHRF1 protein levels and its chromatin association by ChIP‑qPCR.
   • Evaluate histone turnover using H3.3‑FLAG pulse‑chase labeling.
3. Expected outcomes: Berberine‑treated mice will show (a) significantly slower DunedinPACE progression, (b) reduced subtelomeric methylation entropy, (c) increased histone turnover, and (d) decreased UHRF1 chromatin binding relative to controls.
4. Falsifiable criteria: If berberine fails to alter any of the epigenetic entropy markers (methylation variance, histone turnover, UHRF1 binding) despite confirming autophagy activation, the hypothesis is refuted. Likewise, if epigenetic clock slowing occurs without concomitant changes in autophagy or UHRF1, alternative mechanisms must be considered.

Potential Outcomes & Falsifiability

• Supportive result: Concurrent improvements in autophagy, histone renewal, and methylation fidelity correlate with clock deceleration, reinforcing the entropy‑reduction model.
• Refuting result: No change in epigenetic entropy markers despite robust metabolic effects (e.g., AMPK activation, glycemic improvement) would indicate that berberine’s anti‑aging actions operate independently of informational entropy, directing focus toward other pathways such as mitochondrial hormesis or inflammasome modulation.

This framework directly tests whether berberine’s geroprotective impact stems from its capacity to curb the informational entropy that underlies epigenetic aging, offering a clear, falsifiable path forward.